Bevacizumab biosimilar is under clinical development by R-Pharm and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Bevacizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bevacizumab biosimilar overview
Bevacizumab biosimilar (RPH-001) is under development for the treatment of recurrent or metastatic colon, breast, ovarian cancer, as well as non-squamous non-small cell lung cancer, renal cell cancer and glioblastoma
The drug candidate is administered through intravenous route. It is a recombinant humanized monoclonal antibody which acts by targeting human vascular endothelial growth factor A (VEGF-A).
R-Pharm overview
R-Pharm (R Pharm) is a pharmaceutical company. It carries out the production of drugs, active pharmaceutical ingredients, laboratory equipment and high-tech medical systems. The company’s pipeline products include RPH-001, RPH-002, RPH-120, RPH-075, RS-113 and RS-110 for oncology; Nemonoxacin, Narlaprevir, Cefilavancin and Delamanid which targets antimicrobial; Olokizumab, Goflikicept, RPH-035 and Etanercept for anti-infammatory and products. Its therapeutic areas are oncology, nephrology, cardiology, virology and hepatitis, drug treatment, intensive therapy and others. The company collaborates with pharmaceutical and biotechnology companies. It has operations in Russia, the US, Azerbaijan, Uzbekistan, Kyrgyzstan, Kazakhstan, Belarus and Germany. R-Pharm is headquartered in Moscow, Russia.
For a complete picture of Bevacizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
